Indicated for: bone metastases; tumor-induced hypercalcemia
Substance: clodronic acid (bisphosphonate)
ATC: M05BA02 (Musculo-skeletal system | Drugs affecting bone structure and mineralization | Bisphosphonates)
Clodronic acid is a bisphosphonate used to treat osteoporosis and hypercalcemia associated with bone metastases. It helps reduce bone loss by inhibiting osteoclast-mediated bone resorption.
It is commonly used in the treatment of cancer patients with bone metastases, helping to reduce pain and the risk of fractures. It can also be used to treat malignant hypercalcemia, a condition characterized by high calcium levels in the blood.
Clodronic acid is administered either orally or intravenously, depending on the medical indication. Side effects may include nausea, diarrhea, and, in rare cases, impaired kidney function. It is important for patients to strictly follow their doctor's recommendations to minimize risks.
Patients using clodronic acid should be periodically monitored to assess kidney function and blood calcium levels. It is contraindicated in cases of severe renal impairment.